Real-time RT-PCR for the measurement of prostate-specific antigen mRNA expression in benign hyperplasia and adenocarcinoma of prostate

被引:19
作者
Gelmini, S
Tricarico, C
Petrone, L
Forti, G
Amorosi, A
Dedola, GL
Serio, M
Pazzagli, M
Orlando, C
机构
[1] Univ Florence, Dept Clin Physiopathol, Clin Biochem Unit, I-50139 Florence, Italy
[2] Univ Florence, Dept Clin Physiopathol, Endocrinol Unit, I-50139 Florence, Italy
[3] Univ Florence, Dept Clin Physiopathol, Androl Unit, I-50139 Florence, Italy
[4] Univ Florence, Dept Pathol, I-50139 Florence, Italy
[5] Careggi Hosp, Radiodiagnost Unit, Florence, Italy
关键词
PSA mRNA; RT-PCR; fluorogenic probes; biopsy; fine needle;
D O I
10.1515/CCLM.2003.040
中图分类号
R446 [实验室诊断]; R-33 [实验医学、医学实验];
学科分类号
1001 ;
摘要
Since PSA is supposed to play an active role in the progression of prostate cancer, we applied a quantitative RT-PCR to measure the absolute levels of prostate-specific antigen (PSA) mRNA expression in benign and malignant prostatic tissue. Consecutive fine needle prostate biopsy material from 59 patients (43 with prostate adenocarcinoma and 16 with benign prostatic hyperptrophy; BPH) was used for the measurement of PSA mRNA expression. In addition, we evaluated the correlation between PSA synthesis and PSA circulating levels in the same patients. The relationship between PSA mRNA expression and histological grade was also evaluated. PSA mRNA was measured with a quantitative RT-PCR, based on the use of fluorogenic probes, according to the TaqMan reaction system. The mRNA expression for PSA in prostate adenocarcinoma biopsies was highly variable, ranging from 2x10(4) to 2.1x10(8) molecules/pg total RNA with a mean value of 2.5x10(7) and significantly higher (p=0.006) than that found in BPH patients (mean: 1.3x10(6) and range: 6.9x10(2) to 8x10(6)). The mRNA PSA expression in needle biopsy material did not seem to be related to PSA circulating levels in prostate cancer patients (r=0.281), whereas in BPH patients the two parameters correlated significantly (r=0.667, p<0.01). A reduction of PSA mRNA expression in samples with a lower grade of differentiation (Gleason score 9-10) was also observed. Even though a mean increase of PSA expression was demonstrated in cancer samples, this small difference does not confirm a significant role of PSA proteolytic activity in prostate cancer progression. In conclusion, the assay procedure we proposed represents a reliable basis for more extensive study of PSA physiopathology in prostate cancer.
引用
收藏
页码:261 / 265
页数:5
相关论文
共 30 条
[1]   PROSTATE-SPECIFIC ANTIGEN AND GLEASON GRADE - AN IMMUNOHISTOCHEMICAL STUDY OF PROSTATE-CANCER [J].
AIHARA, M ;
LEBOVITZ, RM ;
WHEELER, TM ;
KINNER, BM ;
OHORI, M ;
SCARDINO, PT .
JOURNAL OF UROLOGY, 1994, 151 (06) :1558-1564
[2]  
[Anonymous], UROLOGIC PATHOLOGY
[3]  
Bostwick DG, 1998, CANCER-AM CANCER SOC, V82, P2256, DOI 10.1002/(SICI)1097-0142(19980601)82:11<2256::AID-CNCR22>3.0.CO
[4]  
2-S
[5]   SINGLE-STEP METHOD OF RNA ISOLATION BY ACID GUANIDINIUM THIOCYANATE PHENOL CHLOROFORM EXTRACTION [J].
CHOMCZYNSKI, P ;
SACCHI, N .
ANALYTICAL BIOCHEMISTRY, 1987, 162 (01) :156-159
[6]   VARIATION OF PROSTATE-SPECIFIC ANTIGEN EXPRESSION IN DIFFERENT TUMOR-GROWTH PATTERNS PRESENT IN PROSTATECTOMY SPECIMENS [J].
GALLEE, MPW ;
VISSERDEJONG, E ;
VANDERKORPUT, JAGM ;
VANDERKWAST, TH ;
TENKATE, FJW ;
SCHROEDER, FH ;
TRAPMAN, J .
UROLOGICAL RESEARCH, 1990, 18 (03) :181-187
[7]   Real-time quantitative reverse transcriptase-polymerase chain reaction (RT-PCR) for the measurement of prostate-specific antigen mRNA in the peripheral blood of patients with prostate carcinoma using the TaqMan™ detection system [J].
Gelmini, S ;
Tricarico, C ;
Vona, G ;
Livi, L ;
Della Melina, A ;
Semi, S ;
Cellai, E ;
Magrini, S ;
Villari, D ;
Carini, M ;
Serio, M ;
Forti, G ;
Pazzagli, M ;
Orlando, C .
CLINICAL CHEMISTRY AND LABORATORY MEDICINE, 2001, 39 (05) :385-391
[8]   EVALUATION OF PAP AND PSA GENE-EXPRESSION IN PROSTATIC HYPERPLASIA AND PROSTATIC-CARCINOMA USING NORTHERN-BLOT ANALYSES, IN-SITU HYBRIDIZATION AND IMMUNOHISTOCHEMICAL STAININGS WITH MONOCLONAL AND BISPECIFIC ANTIBODIES [J].
HAKALAHTI, L ;
VIHKO, P ;
HENTTU, P ;
AUTIOHARMAINEN, H ;
SOINI, Y ;
VIHKO, R .
INTERNATIONAL JOURNAL OF CANCER, 1993, 55 (04) :590-597
[9]   PAP AND PSA IN PROSTATIC-CARCINOMA CELL-LINES AND ASPIRATION BIOPSIES - RELATION TO HORMONE SENSITIVITY AND TO CYTOLOGICAL GRADING [J].
HASENSON, M ;
LUNDH, B ;
STEGE, R ;
CARLSTROM, K ;
POUSETTE, A .
PROSTATE, 1989, 14 (02) :83-90
[10]   LATENT PROSTATIC-CANCER IN A CONSECUTIVE AUTOPSY SERIES [J].
HOLUND, B .
SCANDINAVIAN JOURNAL OF UROLOGY AND NEPHROLOGY, 1980, 14 (01) :29-35